BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33497479)

  • 1. High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.
    Okamura R; Piccioni DE; Boichard A; Lee S; Jimenez RE; Sicklick JK; Kato S; Kurzrock R
    Int J Cancer; 2021 Jun; 148(11):2839-2847. PubMed ID: 33497479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.
    Hu Y; Ulrich BC; Supplee J; Kuang Y; Lizotte PH; Feeney NB; Guibert NM; Awad MM; Wong KK; Jänne PA; Paweletz CP; Oxnard GR
    Clin Cancer Res; 2018 Sep; 24(18):4437-4443. PubMed ID: 29567812
    [No Abstract]   [Full Text] [Related]  

  • 3. Dynamics of cell-free DNA in predicting response in adult diffuse glioma on chemoradiotherapy.
    Husain A; Mishra S; Hadi R; Sahu A; Kumari S; Rastogi M; Khurana R; Shukla S; Siddiqui MH; Husain N
    Cancer Genet; 2022 Nov; 268-269():55-63. PubMed ID: 36166960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy.
    Chan HT; Nagayama S; Chin YM; Otaki M; Hayashi R; Kiyotani K; Fukunaga Y; Ueno M; Nakamura Y; Low SK
    Mol Oncol; 2020 Aug; 14(8):1719-1730. PubMed ID: 32449983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer.
    Huang F; Yang Y; Chen X; Jiang H; Wang H; Shen M; Yu Y; Liu T; Pan B; Wang B; Guo W
    Clin Biochem; 2021 Jun; 92():46-53. PubMed ID: 33737000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive landscape and interference of clonal haematopoiesis mutations for liquid biopsy: A Chinese pan-cancer cohort.
    Xu E; Su K; Zhou Y; Gong L; Xuan Y; Liao M; Cao J; Li Y; Lu Y; Zhao Y; Chen F
    J Cell Mol Med; 2021 Nov; 25(21):10279-10290. PubMed ID: 34658138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
    Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
    Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of clonal hematopoiesis and its interference in cell-free DNA profiling of patients with gastric cancer.
    Lee KS; Lee CK; Kwon SS; Kwon WS; Park S; Lee ST; Choi JR; Rha SY; Shin S
    Clin Chem Lab Med; 2024 Jan; 62(1):178-186. PubMed ID: 37435889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing.
    Fairchild L; Whalen J; D'Aco K; Wu J; Gustafson CB; Solovieff N; Su F; Leary RJ; Campbell CD; Balbin OA
    Sci Transl Med; 2023 Mar; 15(689):eabm8729. PubMed ID: 36989374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis.
    Suehara Y; Sakata-Yanagimoto M; Hattori K; Kusakabe M; Nanmoku T; Sato T; Noguchi M; Chiba S
    Cancer Sci; 2019 Oct; 110(10):3375-3381. PubMed ID: 31436356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
    Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A
    JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference.
    Jensen K; Konnick EQ; Schweizer MT; Sokolova AO; Grivas P; Cheng HH; Klemfuss NM; Beightol M; Yu EY; Nelson PS; Montgomery B; Pritchard CC
    JAMA Oncol; 2021 Jan; 7(1):107-110. PubMed ID: 33151258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
    Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
    Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
    Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD
    Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms.
    Cowzer D; Shah RH; Chou JF; Kundra R; Punn S; Fiedler L; DeMore A; Capanu M; Berger MF; Reidy-Lagunes D; Raj N
    Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38252063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational landscape of plasma cell-free DNA identifies molecular features associated with therapeutic response in patients with colon cancer. A pilot study.
    Cervena K; Pardini B; Urbanova M; Vodenkova S; Eva P; Veskrnova V; Levy M; Buchler T; Mokrejs M; Naccarati A; Vodicka P; Vymetalkova V
    Mutagenesis; 2021 Oct; 36(5):358-368. PubMed ID: 34214148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.
    Page K; Guttery DS; Fernandez-Garcia D; Hills A; Hastings RK; Luo J; Goddard K; Shahin V; Woodley-Barker L; Rosales BM; Coombes RC; Stebbing J; Shaw JA
    Clin Chem; 2017 Feb; 63(2):532-541. PubMed ID: 27940449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.